A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab in combination with chemotherapy followed by maintenance therapy of Avelumab in combination with the poly (adenosine diphosphate [Adp] - ribose) polymerase (Parp) inhibitor talazoparib in patients with previously untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100) [B9991030]

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date4/12/18 → 31/12/20

Keywords

  • Medical Oncology
  • Ovarian cancer
  • Clinical trial